William Blair & Company
NAUT icon

William Blair & Company’s Nautilus Biotechnolgy NAUT Stock Holding History

William Blair & Company’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7K Sell
10,000
-5,000
-33% -$13.2K ﹤0.01% 1861
2026
Q1 		$58.2K Buy
+15,000
New +$36.9K ﹤0.01% 1678

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

William Blair & Company's NAUT Position: Q2 2026 in Review

William Blair & Company reduced its Nautilus Biotechnolgy (NAUT) stake by 33% in Q2 2026, selling an estimated $13.2K and leaving 10,000 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

William Blair & Company first reported a position in NAUT in Q1 2026 and has held it in 2 quarters since. The position peaked at $58.2K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • William Blair & Company held 10,000 shares of Nautilus Biotechnolgy worth $18.7K as of Q2 2026.
  • William Blair & Company sold 5,000 Nautilus Biotechnolgy shares in Q2 2026, an estimated $13.2K.
  • Nautilus Biotechnolgy made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1861 holding.
  • William Blair & Company first reported a position in Nautilus Biotechnolgy in Q1 2026 and has held it in 2 quarters since.
  • William Blair & Company's Nautilus Biotechnolgy position peaked at $58.2K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.